Press Releases

Date Title View
Toggle SummaryJanuary 11, 2021 GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020
CARLSBAD, Calif. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2020 .
View HTML
Toggle SummaryDecember 28, 2020 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , Dec. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.
View HTML
Toggle SummaryNovember 5, 2020 GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum
CARLSBAD, Calif. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual
View HTML
Toggle SummaryOctober 28, 2020 GenMark Diagnostics Reports Third Quarter 2020 Results
CARLSBAD, Calif. , Oct. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended September 30, 2020 .
View HTML
Toggle SummaryOctober 14, 2020 GenMark Diagnostics to Report Third Quarter 2020 Financial Results on October 28, 2020
CARLSBAD, Calif. , Oct. 14, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Wednesday, October 28, 2020. Management will hold a conference call to review the company's financial
View HTML
Toggle SummaryOctober 8, 2020 GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) Receives EUA from FDA
Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season RP2 Panel at a Glance GenMark’s ePlex ®   Respiratory Pathogen Panel 2 ( RP2 Panel) has received Emergency Use Authorization from the FDA.
View HTML
Toggle SummaryOctober 8, 2020 GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020
Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth CARLSBAD, Calif. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary
View HTML
Toggle SummarySeptember 14, 2020 GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) achieves CE Mark
Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens helps health care professionals prepare for flu season RP2 Panel at a Glance GenMark’s ePlex® Respiratory Pathogen Panel 2 ( RP2 ) has achieved CE mark. RP2 provides results in less than two hours for more than
View HTML
Toggle SummaryAugust 17, 2020 GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor® SARS-CoV-2 Test
Leveraging GenMark’s eSensor XT-8® platform to expand COVID-19 diagnostic testing capacity CARLSBAD, Calif. , Aug. 17, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that it has notified
View HTML
Toggle SummaryAugust 4, 2020 GenMark Diagnostics Reports Second Quarter 2020 Results
CARLSBAD, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2020 . Second Quarter 2020 Highlights Total revenue of
View HTML